Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. lifted its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 36.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,753,764 shares of the company’s stock after purchasing an additional 469,554 shares during the quarter. Principal Financial Group Inc.’s holdings in Structure Therapeutics were worth $84,531,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in shares of Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after buying an additional 8,444 shares during the period. Invesco Ltd. raised its position in Structure Therapeutics by 7.6% during the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after acquiring an additional 30,162 shares during the period. Marshall Wace LLP raised its position in Structure Therapeutics by 474.9% during the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after acquiring an additional 145,434 shares during the period. Jump Financial LLC lifted its holdings in Structure Therapeutics by 105.9% during the second quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after purchasing an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in Structure Therapeutics during the second quarter valued at $3,480,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 7.2%

GPCR stock opened at $46.03 on Friday. The business has a fifty day moving average of $44.15 and a two-hundred day moving average of $56.58. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -52.91 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $15.80 and a 52-week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GPCR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Wolfe Research initiated coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. Finally, HC Wainwright reduced their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.55.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.